We report here a thorough structure-activity relationship (SAR) with piperazinylureido sulfamates as inhibitors of human (h) carbonic anhydrase (CA, EC 4.2.1.1). A SAR investigation over the structure of reported anti-cancer zinc-binder CAIs such as SLC-0111 and S4 was carried out by including the urea outer nitrogen atom into a substituted piperazine ring reducing the linker flexibility. The derivatives were assessed for the inhibition of CA I, II and IV (off-target isoforms) and the tumor-associated CA IX (anticancer drug target). CA I and IV were not effectively inhibited, whereas many low nanomolar inhibitors were evidenced against CA II (KIs in the range of 1.0–705.5 nM), and IX (KIs in the range of 0.91–155.9 nM). Interestingly, a subset of CA II/IX selective inhibitors was detected which might represent interesting lead for the development of new anticancer strategies.

Sulfonamide/sulfamate switch with a series of piperazinylureido derivatives: Synthesis, kinetic and in silico evaluation as carbonic anhydrase isoforms I, II, IV, and IX inhibitors

Moi, Davide
Co-primo
;
Deplano, Alessandro;Balboni, Gianfranco;Onnis, Valentina
Ultimo
2020-01-01

Abstract

We report here a thorough structure-activity relationship (SAR) with piperazinylureido sulfamates as inhibitors of human (h) carbonic anhydrase (CA, EC 4.2.1.1). A SAR investigation over the structure of reported anti-cancer zinc-binder CAIs such as SLC-0111 and S4 was carried out by including the urea outer nitrogen atom into a substituted piperazine ring reducing the linker flexibility. The derivatives were assessed for the inhibition of CA I, II and IV (off-target isoforms) and the tumor-associated CA IX (anticancer drug target). CA I and IV were not effectively inhibited, whereas many low nanomolar inhibitors were evidenced against CA II (KIs in the range of 1.0–705.5 nM), and IX (KIs in the range of 0.91–155.9 nM). Interestingly, a subset of CA II/IX selective inhibitors was detected which might represent interesting lead for the development of new anticancer strategies.
2020
metalloenzyme; inhibitor; bioisoster; antitumor; selectivity
File in questo prodotto:
File Dimensione Formato  
EJMC_piperazinilureidosulfamates_2020.pdf

Solo gestori archivio

Descrizione: Articolo principale versione editoriale
Tipologia: versione editoriale (VoR)
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Manuscript_ONNIS_revised.pdf

accesso aperto

Descrizione: articolo principale
Tipologia: versione pre-print
Dimensione 1.38 MB
Formato Adobe PDF
1.38 MB Adobe PDF Visualizza/Apri
ms+piperazinsulfamati_SupplMat_ONNIS_revised.pdf

accesso aperto

Descrizione: materiale supplementare
Tipologia: versione pre-print
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/280766
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 17
social impact